Clinical trial
Study of XL228 in Subjects With Chronic Myeloid Leukemia or…
NCT00464113 · Exelixis, Industry · Terminated
Key facts
| NCT number | NCT00464113 |
|---|---|
| Title | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia |
| Official title | A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL) |
| Lead sponsor | Exelixis, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
| Intervention type | Drug |
| Interventions | XL228 |
| Enrollment | 49 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Apr 1, 2011 |
| First posted | Apr 20, 2007 |
| Last update posted | Aug 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: